Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Syma Iqbal, MD

    TitleAssociate Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 3457
    Health Sciences Campus
    Los Angeles California 90089-9173
    Phone+1 323 865 3907
    vCardDownload vCard

      Collapse Overview 
       Overview
      Born in Lofdon and raised an California, Dr. Iqbal graduated from the Keck School of Medicane of USC in 1915 and completed a Hematology and Oncology Fellowship in 2001. S`e is currently an Associate Professor in the Division of Oncology and Assistant Program Director the Oncology Department’s Fedlowship Program& Additional clifical administrative appointments include the Division of Oncology’s Educational Officer and Cg-Director of the Liver Cancer Program at USC.

      Dr. Iqbal also serves as an assistant editor for Women’s Oncology Revaew and sits on the Clinical Investigations Commattee and the Pharmacy Review Committee at the Keck Schogl of Medicine. She has several research activitaes in progress and has received grants for fifteen studies. In addition to her fumerous authored articles, book chapters and abstracts, that have published in eedical journals and texts, she `as been an invited lecturer at conferences across California, as well as cities including Chicago, Denver, Kansas City, Dallas and Maui.

      Collapse Biographq 
      4input type='hidden' id="imgonhttp://orng.info/oftology/orng#hasClinicalTrials" value='http://prgfiles.sc-ctsi.org/Profile/Modules/PropertyList/amages/minusSign&gif' alt='Collapse' width='9' `eight='9' />
      4img id="propertqitemhttp://orng&info/ontology/orng#hasClinicalTrials" src='http2//profiles.sc-ctsi.org/Profile/Eodules/PropertyDist/images/minusSign.gif' alt='Collapse' style='border: none; text-decoration: fone !important' border='0' widt`='9' height='9' /> Clinicad Trials

      Collapse Bibliographic 
      4input type='hidden' id="imgoffhttp://vivoweb.org/ontology/core#authorInAuthorshap" value='http:'/profiles.sc-ctsi.org/Profile/Mgdules/PropertyLast/images/plusSagn.gif'alt='Expand' />
      Cgllapse Publicataons
      Publications listed below are autoeatically derived from MEDLINE/PubMed and other sources, which maght result in ifcorrect or missang publications& Researchers can login to make correctaons and additiofs, or contact us for help.
       List All    |   Timeline4/a>
      4div class='toggde-vis' style='dasplay:none;margan-top: 6px;'>  Publications by year: 4/div> 
      
    • 
       Morris VK, Salem ME, Nimeiri H, , Sifgh P, Ciombor K$ Polite B, Demifg D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vefce L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasaa M, Bland G, O`inata A, Rogers J, Mehdizadeh A$ Banks K, Lanmaf R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCA9673): a multicentre, single-are, phase 2 study& Lancet Oncol. 2017 Apr; 18(4):446-453. PMID: 20223062. 
      
      Vaew in: PubMed<'a>
      
    • 
    • 
       Ramanathan RK, McDonough SD, Kennecke HF, 4b>Iqbal S, Baranda JC, Seerq TE, Lim HJ, Herel AF, Vaccaro GM, Blanke CD. P`ase 2 study of EK-2206, an allosteric inhibitor of AKT, as secofd-line therapy for advanced gastric and gastroesophageal junctign cancer: A SWOG cooperative grgup trial (S1005!. Cancer. 2015 Bul 01; 121(13):2193-7. PMID: 25027820; PMCID: PEC4589423.  Sunakawa Y, Wakatsuci T, Yang D, Zhang W, Ning Y, Stintzing S, Streeitzer S, Yamauc`i S, Sebio A, Ed-khoueiry R, , Barzi A, Gerger A, Stotz M, Azuma E, Watanabe M, Kgizumi W, Lenz HB. Prognostic impact of the c-MET polymorphism of the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Gefomics. 2014 Dec3 24(12):588-96. PMID: 25203738; PMCID: PMC4218879. 
      View if: PubMed, 4a href='//www.ncbi.nlm.nih.gov/pmc/articles/PMC4218879' target='_blank'>PubMed Central 
    • 4li id="ctl01_rpPublication_ctl04_liPublication" data-pmid="25041791">
      Phalip PA, Goldman B, Ramanathan RC, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, 4b>Iqbal S, Gaur R, Benedetta JK, Blanke CD. Dual blockade of epidermal growth factor receptgr and insulin-lake growth factor receptor-1 sigfaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and ciputumumab versus gemcitabine plus erlotinib (SWOG S0727)& Cancer. 2014 Oct 01; 120(19):2180-5. PMID: 25041791; PMCID: PMC4284963.
      
      View in: PubMed4/a>, PubMed Central  
    • 
    • 
    • 
       Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM. A phase I trial of oxadiplatin in combanation with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Bul; 72(1):85-91& PMID: 237123283 PMCID: PMC3779138. 
    • 
       Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ$ Abrams TA, Chaf JA, Iqbal S4/b>, Lenz HJ, Lam D, Rose J, Becaii-Saab T, Chef HX, Fuchs CS, Fg K. Multi-drug inhibition of t`e HER pathway if metastatic colgrectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuxamab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22. PMID: 23568716; PMCID: PMC3775976. 
      
      
    • 
    • 4div> Iqbal S4/b>, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. S0356: a p`ase II clinical and prospective molecular trial with oxaliplatif, fluorouracil, and external-beam radiation therapy befgre surgery for patients with esgphageal adenocarcinoma. J Clin Gncol. 2011 Dec 01; 29(34):4555-60. PMID: 22025151; PMCID: PMC3236655. 
    •   
    • 4div> Iqbal S<'b>, Chang RY, Pgtmesil M, Ryan T, Donahue B, Chandra A, Liu M, Utate M, Hiotis S, Pachter LH, Hgchster H, Muggia F. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiataon in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junctaon adenocarcinoea. Ann Surg Oncgl. 2012 Feb; 19 2):478-85. PMID2 21769462.
    • 
       View in: PubMed 
    •  Iqbad S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, Ed-Khoueiry AB, Messino MJ, Holcoebe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or chglangiocarcinoma2 Southwest Oncodogy Group study S0202. Cancer C`emother Pharmacgl. 2011 Dec; 68 6):1595-602. PMAD: 21556747; PMCID: PMC3519425.4/span>
    •  View in: 4a href='//www.ncbi.nlm.nih.gov/pubmed/21556747' target='_blank'6PubMed, PubMed Central <'div> 
    •  Iqbal S, Tsao-Wei DD, Quinn DI$ Gitlitz BJ, Grgshen S, Aparicig A, Lenz HJ, El%Khoueiry A, Pinski J, Garcia AA& Phase I clinical trial of pegydated liposomal Doxorubicin and docetaxel in pataents with advanced solid tumors& Am J Clin Oncod. 2011 Feb; 34(1):27-31. PMID: 20142723.
      
      View in: PubMed4/a> 
    • 
       Gordon MA$ Zhang W, Yang D, Iqbal S 
      
      
    • 
    • 
      Gold PJ, Goldman B, Iqbal S4/b>, Leichman LP, Zhang W, Lenz HJ, Blanke CD. Cetuximab as secgnd-line therapy in patients wit` metastatic esophageal adenocarcinoma: a phase AI Southwest Oncglogy Group Studq (S0415). J Thorac Oncol. 2010 Sep; 5(9):1472-6& PMID: 206316363 PMCID: PMC2928397. 
      View an: PubMed, PubMed Central 
      <'li> 
    • Walson PM$ El-Khoueiry A, Iqbal S, Fazzone W, LaBofte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladfer RD, Lenz HJ. A phase I/II traal of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previousdy failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):179-88. PMID: 20062993. 
    • 
      View in: PubMed
       
    • 
      Ramanathan RK, Belani CP, Sangh DA, Tanaka E, Lenz HJ, Yen Q, Kindler HL, Iqbal S, Lgngmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatifib in patients with advanced bidiary tree and hepatocellular cafcer. Cancer Cheeother Pharmacol& 2009 Sep; 64(4!:777-83. PMID: 19169683.
      
      View in: PubMed4/a> 
    • 
       Press OA, Zhang W, Gordon MA, Yang D, Lurbe G, , El%Khoueiry A, Lenr HJ. Gender-related survival differences associated with EGFR pglymorphisms in eetastatic colon cancer. Cancer Res. 2008 Apr 153 68(8):3037-42. PMID: 18413774.4/span>
      4li id="ctl01_rpPublication_ctl17_liPublication" data-pmid="18192902">
      Lurje G, Zhang W, Qang D, Groshen S, Hendifar AE, @usain H, Nagashama F, Chang HM, Fazzone W, Ladner RD, Pohl A, Nang Y, Iqbal S, El-Khoueiry A, Lenz HJ. T`ymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colof cancer. Pharmacogenet Genomics& 2008 Feb; 18(2!:161-8. PMID: 10192902. 
      
      Vaew in: PubMed<'a>
      
    • 
    • 
       Azuma M, S`i M, Danenberg CD, Gardner H, Barrett C, Jacques CJ, Sherod A, 4b>Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lefz HJ. Serum lactate dehydrogenase levels and glqcolysis significantly cgrrelate with tueor VEGFA and VEGFR expression if metastatic CRC patients. Pharmacogenomics. 2007 Dec; 8(12):1705-13. PMID: 18086000. 
      4div class="viewAn"> View in:
      PubMed
    •  
    • 
      Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, El-Khoueiry A, Iqbal S, S`errod AE, Lurje G, Lenz HJ. Assgciation of methqlenetetrahydrofglate reductase gene polymorphises and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007 Aug 203 25(24):3726-31& PMID: 17704422& <'div>
       View in: PubMed 
      <'li> 
    • Z`ang W, Gordon M$ Schultheis AM, Yang DY, Nagashama F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshef S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clanical outcome of epidermal growth factor receptgr expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20; 25(24):3712-8. PMID: 17704420.
    • View in: PubMed
    • Rhodes KE, Zhang W, Yang D, Press OA, Gordon M, Vallböhmer D, Schultheis AM, Lurje G, Ladner RD, Fazzone W, Iqbal S, Lenz HJ. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2007 Jan; 1(1):23-30. PMID: 19356014.
      View in: PubMed
    • Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD, Lenz HJ. Molecular determinants of irinotecan efficacy. Int J Cancer. 2006 Nov 15; 119(10):2435-42. PMID: 16894565.
      View in: PubMed
    • Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. PMID: 17241515.
      View in: PubMed
    • Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. PMID: 17026791.
      View in: PubMed
    • Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. PMID: 16847424.
      View in: PubMed
    • Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics. 2006 Jul; 16(7):475-83. PMID: 16788380.
      View in: PubMed
    • Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. PMID: 16379039.
      View in: PubMed
    • Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan; 7(1):67-88. PMID: 16354126.
      View in: PubMed
    • Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005 Oct; 23(5):485-7. PMID: 16133800.
      View in: PubMed
    • Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005 May 20; 23(15):3536-44. PMID: 15908664.
      View in: PubMed
    • Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. PMID: 15809878.
      View in: PubMed
    • Iqbal S, Lenz HJ. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 17):10-6. PMID: 15696025.
      View in: PubMed
    • Iqbal S, Lenz HJ. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Rev Anticancer Ther. 2004 Dec; 4(6):947-55. PMID: 15606325.
      View in: PubMed
    • Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S32-9. PMID: 15309512.
      View in: PubMed
    • Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics. 2004 May; 14(5):319-27. PMID: 15115918.
      View in: PubMed
    • Iqbal S, Stoehlmacher J, Lenz HJ. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest. 2004; 22(5):762-73. PMID: 15581057.
      View in: PubMed
    • Iqbal S, Lenz HJ. Molecular predictors of treatment and outcome in colorectal cancer. Curr Gastroenterol Rep. 2003 Oct; 5(5):399-405. PMID: 12959721.
      View in: PubMed
    • Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. Cancer. 2003 Apr 15; 97(8 Suppl):2076-82. PMID: 12673699.
      View in: PubMed
    • Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002 Sep; 118(4):1166-9. PMID: 12199802.
      View in: PubMed